Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernhard Manger

Showing results (131-140 of 134) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 134 results.
Nature Communications|July 26, 2020
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversionDavid Simon, Koray Tascilar, Gerhard Krönke, et al.
The Lancet. Rheumatology|August 15, 2022
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort studyDavid Simon, Koray Tascilar, Filippo Fagni, et al.
Lancet (London, England)|February 16, 2024
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trialJuergen Rech, Koray Tascilar, Melanie Hagen, et al.
Annals of the Rheumatic Diseases|September 11, 2019
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of goutDavid Bursill, William J Taylor, Robert Terkeltaub, et al.
Pageof 14

Showing results (131-140 of 134) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 134 results.
Nature Communications|July 26, 2020
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversionDavid Simon, Koray Tascilar, Gerhard Krönke, et al.
The Lancet. Rheumatology|August 15, 2022
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort studyDavid Simon, Koray Tascilar, Filippo Fagni, et al.
Lancet (London, England)|February 16, 2024
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trialJuergen Rech, Koray Tascilar, Melanie Hagen, et al.
Annals of the Rheumatic Diseases|September 11, 2019
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of goutDavid Bursill, William J Taylor, Robert Terkeltaub, et al.
Pageof 14